3Broskey J, Coleman K, McClosmen K, et al. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptoocus pneumoniae. J Antimicrob Chemother, 2000, 45(Suppl 1) :95.
4Bertino J Jr, Fish D. The safety profile of the fluoroquinolones. Clin Ther, 2000, 22:798.
5Hampel B, Hullmamm R, Sxhmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use-safety report. Pediatr Infect Dis J, 1997, 16:127.
6Redmond A, Sweeney J, MacFarland M, et al.Oral ciprofloxacin in the treatment of pseudomonas exacerbations of pediatric cystic fibrosis: clinical efficacy and safety evalution using magnetic resonance image scanning. J Int Med Res, 1998, 26:304.
7Schaad UB, Wedgwood-Krucho J, Guenin K, et al. Antiseudomonql therapy in cystic fibrosis:aztreonam and amikacin versus ceftazidine and amikacin administered intravenously followed by oral ciprofloxacin. Eur J Clin Microbiol Infect Dis,1989, 8:858.
8Rubio TT. Ciprofloxacin in the treatment of Psudomonas infection in children with cystic fibrosis.Diagn Microbiol Infect Dis, 1990, 13:153.
9Schaad UB, Stoupis C, Wedgwood-Krucko J, et al.Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin. Pediatr Infect Dis J, 1991, 10:723.
6[2]MichineM. Toxicokineticstudy of norFloxacin-induced arthropathy in juvenile animals. Toxicol Appl Pharmacol.1990,105:403
7[4]Schaad UB. Use of fluoroquinolone in Pediatrics:consensus report of an international society of chemotherapy commission. Pediatr Infect DisJ.1995,14(1):1.
